A. Goldhirsch - Concepedia

Author

A. Goldhirsch

European Institute of Oncology

Also Known As

A GOLDHIRSCH, A Goldhirsch, A. Goldhirsch, Aran Goldhirsch, JF Forbes

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

European Institute of Oncology University of Milan International Breast Cancer Study Group Dana-Farber Cancer Institute Ospedale regionale di Lugano

About

A. Goldhirsch is an author at European Institute of Oncology specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	772
2	Health Sciences	4	4	149
3	Nursing	1	1	177
4	Biochemistry	1	1	15
5	Cell Biology	1	1	40

A. Goldhirsch

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. C. Focan, S. M. Steinberg, M Blichert-Toft, PubMed	1998	2.2K
The requirements of a specialist Breast Centre A.R.M. Wilson, Lorenza Marotti, Simonetta Bianchi, European Journal of Cancer NursingPrimary CareSpecialist Breast CentreAesthetic SurgeryBreast Imaging	2013	177
Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial Prudence A. Francis, John Crown, Angelo Di Leo, JNCI Journal of the National Cancer Institute	2008	149
First—select the target: better choice of adjuvant treatments for breast cancer patients A. Goldhirsch, Alan S. Coates, Richard D. Gelber, Annals of Oncology Surgical OncologyOncologyBreast OncologyBreast Cancer PatientsCancer Management	2006	99
Cancer–testis antigen expression in triple-negative breast cancer Giuseppe Curigliano, Giuseppe Viale, Mariacristina Ghioni, Annals of Oncology Breast OncologyBreast CancerCancer–testis Antigen ExpressionMedicineRadiation Oncology	2010	96
Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer Elisabetta Munzone, Edoardo Botteri, Angela Sciandivasci, Breast Cancer Research and Treatment Tumor BiologyBreast OncologyOncologyMedicinePrognostic Value	2012	71
The Triple-Negative Subtype: New Ideas for the Poorest Prognosis Breast Cancer Giuseppe Curigliano, A. Goldhirsch JNCI Monographs	2011	55
The concept of an overview of cancer clinical trials with special emphasis on early breast cancer. R.D. Gelber, A. Goldhirsch Journal of Clinical Oncology International CooperationBreast OncologyEarly Breast CancerMedicineProspective Protocol	1986	52
Preoperative versus postoperative docetaxel–cisplatin–fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial Nicola Fazio, Roberto Biffi, Rudolf Maibach, Annals of Oncology Surgical Oncology10-Year Follow-upGastrointestinal OncologyMedicinePhase Iii Trial	2015	47
Abstract S5-2: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up A. Goldhirsch, M.J. Piccart-Gebhart, Marion Procter, Cancer Research Median FuBreast OncologyMedicineHera TrialT Arms	2012	46

Page 1